The merger is on track for Q4 2026 close; the key catalyst is the CRPS-RISE topline data readout expected in 2028. Watch for shareholder vote and any regulatory updates on the interim analysis design.
Drug in focus
HOWL drug pipeline →neridronate
● Neutral Named in this 425- Impact
- Phase
- Phase 3
- Time to market
- Topline Phase 3 results expected in 2028, NDA submission thereafter, potential FDA approval likely no earlier than 2029 if the trial succeeds.
- Next catalyst
- None dated
What to watchWatch for the timing and outcome of the CRPS-RISE interim analysis, which could allow the trial to stop early for efficacy or futility. The merger with Ambros is still being finalized (S-4/A filed November 10, 2026), and current HOWL shareholders face massive dilution, owning roughly 7% of the combined entity. The $150 million PIPE is expected to fund the company through topline results in 2028 and into 2029, reducing near-term financing risk.
- ▼ WTX-124 3/10 unknown — not confirmed this session (SecBot's FDA/ClinicalTrials.gov ingestion holds no WTX-124 records; external web s
- ● WTX-330 2/10 Unknown/unverified — no Phase 2/3 industry-sponsored records for WTX-330 exist in SecBot's ingested ClinicalTrials.gov d
- All HOWL drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $0.9700entry
- T+1 · 6d ago +1.95%α +0.63% · $0.9889
- T+4 · todayOpen
- T+5 · in 6h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ambros Therapeutics presented an Analyst Day deck detailing its pending reverse merger with Werewolf Therapeutics (HOWL), including a concurrent $150M PIPE co-led by RA Capital Management and Janus Henderson Investors. The combined company is valued at ~$697.5M pro forma, with Ambros implied at $500M and Werewolf at $47.5M. The deal is expected to close in Q4 2026, and the combined entity will trade as 'AMBX' with proceeds funding the CRPS-RISE pivotal trial of neridronate through NDA submission.
Key Financial Metrics
Key Facts
- Reverse triangular merger of Werewolf subsidiary into Ambros; Ambros survives as wholly owned subsidiary.
- Pro forma combined company value at closing: ~$697.5M.
- Implied valuation for Ambros: $500M (before concurrent PIPE).
- Implied valuation for Werewolf: $47.5M ($30M net cash + $17.5M Nasdaq listing value).
- Concurrent PIPE financing: $150M, co-led by RA Capital Management and Janus Henderson Investors.
- Pro forma ownership: ~72.0% Ambros, ~6.4% Werewolf, ~21.6% PIPE investors.
- Post-closing ticker: AMBX on Nasdaq.
- Proceeds to fund CRPS-RISE pivotal trial, regulatory activities through NDA submission, and pre-commercial activities.
- Expected close: Q4 2026.
- Neridronate is a bisphosphonate approved in Italy for CRPS; FDA granted Breakthrough Therapy, Fast Track, and Orphan Drug Designations.
- Pivotal Phase 3 CRPS-RISE trial (NCT07210515) is recruiting, targeting ~270 patients with primary endpoint at Week 12.
- FDA agreed to include an interim analysis with group sequential design; trial could stop early for efficacy.
- Ambros had ~$103.2M in cash, cash equivalents, and short-term investments as of June 30, 2026 (unaudited).
- Abiogen Pharma holds >5% of Ambros post-merger; Ambros pays transfer price (COGS + low double-digit markup) and mid-single-digit royalty on net sales.
Financial Impact
Combined pro forma enterprise value ~$697.5M; $150M PIPE; Werewolf legacy holders get ~6.4% of combined entity; Ambros valued at $500M.
Risk Factors
- Merger requires stockholder approval and other closing conditions; risk of delay or failure to close.
- CRPS-RISE trial may not meet its primary endpoint; interim analysis may not stop early for efficacy.
- FDA may require additional clinical data beyond the single Phase 3 study for NDA approval.
- Neridronate faces potential competition from other bisphosphonates and existing pain management therapies.
- Reliance on Abiogen for manufacturing and supply; any disruption could delay development.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001140361-26-042855 |
| Document: 0001140361-26-042855-index-headers.html | 0001140361-26-042855 |
| Document: 0001140361-26-042855-index.html | 0001140361-26-042855 |
| Document: 0001140361-26-042855.txt | 0001140361-26-042855 |
Track record
31 reports on HOWL
12 of 16 bullish or bearish reports moved the stock their way by T+5. Best: +51.32% at T+60 after the Apr 27, 2026 report. 13 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $0.9500 Now $0.9910 +4.32% settles Nov 23
- Nov 13, 20264d ago EFFECT Neutral 4/10 Entry $0.9803 Now $0.9910 +1.09% settles Nov 20
- Nov 10, 20266d ago S-4/A Neutral 5/10 Entry $0.9889 Now $0.9910 +0.21% settles Nov 18
- Nov 9, 20267d ago 425 Neutral 5/10 Viewing Entry $0.9700 Now $0.9910 +2.16% settles Nov 17
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $1.01 to $0.9908 Now $0.9910 −1.88% ▼ −1.90% −0.21% vs SPY
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $1.01 to $0.9908 Now $0.9910 −1.88% ▼ −1.90% −0.21% vs SPY
- Oct 26, 202621d ago S-4/A Bearish 5/10 Entry $1.04 to $1.07 Now $0.9910 +4.71% ▼ −2.88% −4.87% vs SPY
- Sep 22, 20267w ago S-4 Bearish 7/10 Entry $0.9894 to $0.9223 Now $0.9910 −0.16% ▲ +6.78% +6.11% vs SPY
- Sep 21, 20268w ago SC 13G Neutral 3/10 Entry $0.9800 to $0.9300 Now $0.9910 +1.12% ▼ −5.10% −4.08% vs SPY
- Aug 21, 202612w ago 425 Bullish 7/10 Entry $0.8740 to $0.9433 Now $0.9910 +13.39% ▲ +7.93% +7.46% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers